Pediatric Claim For Guerbet’s Imaging Agent Dotarem Questioned By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
In advisory committee briefing documents, agency reviewers cite limitations in gadoterate’s pediatric experience, particularly among patients two years of age and younger. This is the key population that would differentiate Dotarem from other gadolinium-based contrast agents already on the market.
You may also be interested in...
Guerbet Looks To Separate Dotarem In Crowded Contrast Agent Market
FDA advisory committee scheduled for Valentine’s Day is key test for Guerbet’s efforts to get its MRI imaging agent a wider indication than Bayer’s Gadavist.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.